• Merck and Eisai Ink $5.76B Cancer Deal biospace
    March 09, 2018
    Merck & Company and Tokyo-based Eisai Inc. have signed a strategic collaboration deal to develop and commercialize Lenvima (lenvatinib mesylate) with Merck’s anti-PD-1 drug Keytruda (pembrolizumab).
PharmaSources Customer Service